Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

Fig. 2

Treatment persistence at 6-month (a) and 12-month (b) follow-up among first-line initiators of ETN, ADA, and JAKis. Patients who discontinued therapy included those who had withdrawn therapy but not switched and those who switched to another b/tsDMARD. ADA, adalimumab; b/tsDMARD, biologic/targeted synthetic disease-modifying antirheumatic drug; ETN, etanercept; JAKi, Janus kinase inhibitor

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us